
Journal of Medicinal Chemistry p. 686 - 694 (1995)
Update date:2022-08-04
Topics:
Faull, Alan W.
Brewster, Andrew G.
Brown, George R.
Smithers, Michael J.
Jackson, Ruth
The design, synthesis, and pharmacology of a new class of compounds possessing bith thromboxane receptor antagonist and thromboxane synthase inhibitory properties are described.Replacement of the phenol group of the known thromboxane antagonist series 4(Z)-6-<(4RS,5SR)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl>hex-4-enoic acid by a 3-pyridyl group led to a series of compounds, 5, which were potent thromboxane synthase inhibitors and weak thromboxane antagonists.Further modifications at the dioxane C2 position led to compounds, 7, which were potent dual-acting agents.In the case of compound 7w, the dual activity was shown to reside almost exclusively in the (-)-enantiomer, 7x.Following oral dosing to rats and dogs, 7x (3 mg/kg) displayed significant dual activity over a period of at least 8 h.
View MoreTIANJIN FESTO CHEMICAL CO.,LTD(expird)
Contact:86-22-25814570
Address:No.12th,5th Ave.,TEDA,Tianjin,China
Improve Medical Technology(Nanxiong) Co., Ltd
Contact:86-751-3836997
Address:No.33, Pingan First Road, Fine Chemical Industry Base, Nanxiong City, Shaoguan, Guangdong, China
ABA Chemicals (Shanghai) Limited
Contact:021- 5115 9199-232
Address:Suite 18D, #201 Ningxia Road,
chengdu firsterchem Pharmaceutical Co., Ltd.
Contact:028-66825849
Address:chengdu
Weifang Arylchem Chemical Co., LTD
Contact:86-536-5217866
Address:Development Zone, Shouguang, Shandong Province
Doi:10.1002/hlca.19930760709
(1993)Doi:10.1016/S0040-4039(00)60337-4
(1993)Doi:10.1007/BF00863826
(1992)Doi:10.1055/s-0033-1339690
(2013)Doi:10.1016/j.ejmech.2017.04.049
(2017)Doi:10.3390/molecules20046153
(2015)